| __timestamp | Merus N.V. | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 3852327 | 1802274 |
| Thursday, January 1, 2015 | 839656 | 2512761 |
| Friday, January 1, 2016 | 4478145 | 2894488 |
| Sunday, January 1, 2017 | 16432324 | 8096274 |
| Monday, January 1, 2018 | 11890871 | 7985229 |
| Tuesday, January 1, 2019 | 34110000 | 8994597 |
| Wednesday, January 1, 2020 | 35781000 | 29772000 |
| Friday, January 1, 2021 | 40896000 | 33907000 |
| Saturday, January 1, 2022 | 52200000 | 26579000 |
| Sunday, January 1, 2023 | 59836000 | 49868547 |
Unleashing the power of data
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of two prominent players: Verona Pharma plc and Merus N.V., from 2014 to 2023. Over this period, Merus N.V. has seen a staggering increase in SG&A expenses, growing by over 1,450%, from approximately $3.85 million in 2014 to nearly $59.84 million in 2023. Verona Pharma plc, while also experiencing growth, has seen a more moderate increase of around 2,670%, with expenses rising from $1.80 million to $49.87 million in the same timeframe. This trend highlights the aggressive expansion and operational scaling of these companies. As the biotech industry continues to evolve, understanding these financial dynamics offers valuable insights into strategic business decisions and market positioning.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
Breaking Down SG&A Expenses: Amgen Inc. vs Merus N.V.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Merus N.V.
Teva Pharmaceutical Industries Limited and Verona Pharma plc: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Verona Pharma plc
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Merus N.V.
SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Merus N.V.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Veracyte, Inc. vs Merus N.V.: SG&A Expense Trends